Thus, combining PCSK9 inhibitors with anti-PD-1/PD-L1 immunotherapy may be a new strategy to improve antitumor effects. Research advances Proprotein convertases (PCs) are a unique class of serine ...

Though currently experimental, this mechanism could complement existing PD-1 and PD-L1 checkpoint inhibitors and improve patient outcomes. How Checkpoint Inhibitors Work Checkpoint inhibitors are ...

Studies presented at the ASCO Annual Meeting 2025 highlighted immunotherapies that may provide new standards of care for ...

PD-1 deficiency enhances Treg cell pro-tumor function : Lim et al. demonstrate that Treg cells deficient in PD-1 occupy key spatial niches within the TME, with regulatory subsets organized near ...

Co-author Dr Kenji Chamoto, from Kyoto University, says, "PD-1 inhibition has a 'yin and yang' nature: it activates anti-tumor immunity but at the same time impedes B-cell immunity.

PD-1 and PD-L1 inhibitors are immunotherapies designed to block this mechanism, allowing the immune system to recognize and attack tumors. To get know more ... (Summit Therapeutics) – A new PD-1/PD-L1 ...

Mechanism of action. Durvalumab targets PD-L1, a key immune checkpoint. Normally, antigen-presenting cells (APCs) recognize cancer cell antigens and activate cytotoxic T cells, which travel to the ...

We are excited to explore the potential of our PD-1 inhibitor, tislelizumab, in combination with ANKTIVA,” said John V. Oyler, Co-Founder, Chairman and CEO of BeiGene. “I’ve admired Dr.

(NYSE American: MAIA), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, ...

According to Akeso, the HARMONi-6 trial marks ivonescimab’s third Phase III success in lung cancer and its second head-to-head win over a PD-1 inhibitor.1 Currently, the treatment is approved in China ...